Jacalyn Rosenblatt

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Immunomodulatory effects of vitamin D: implications for GVHD
    J Rosenblatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bone Marrow Transplant 45:1463-8. 2010
  2. pmc Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Cancer Res 19:3640-8. 2013
  3. pmc PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 34:409-18. 2011
  4. pmc Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 33:155-66. 2010
  5. doi request reprint MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells
    Dina Stroopinsky
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 73:5569-79. 2013
  6. pmc Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
    Baldev Vasir
    Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Immunol 181:808-21. 2008
  7. pmc Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Blood 117:393-402. 2011
  8. pmc Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC)
    Baldev Vasir
    Dana Farber Cancer Institute, Center for Molecular Orthopaedics, Brigham and Women s Hospital, Boston, MA, USA
    J Immunother 35:555-69. 2012
  9. ncbi request reprint Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation
    Baldev Vasir
    Department of Medical Oncology and Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 129:687-700. 2005
  10. doi request reprint Lenalidomide enhances anti-myeloma cellular immunity
    Katarina Luptakova
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Cancer Immunol Immunother 62:39-49. 2013

Collaborators

Detail Information

Publications23

  1. doi request reprint Immunomodulatory effects of vitamin D: implications for GVHD
    J Rosenblatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bone Marrow Transplant 45:1463-8. 2010
    ..These data suggest that exposure to vitamin D results in immature DC populations that bias toward tolerizing rather than stimulatory T-cell populations. Vitamin D may therefore have a role in the prevention of GVHD...
  2. pmc Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Clin Cancer Res 19:3640-8. 2013
    ..We report on the results of a phase II trial in which patients underwent vaccination following autologous stem cell transplantation (ASCT) to target minimal residual disease...
  3. pmc PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 34:409-18. 2011
    ..In summary, we demonstrate that PD-1 expression is increased in T cells of patients with active myeloma, and that CT-011 enhances activated T-cell responses after DC/tumor fusion stimulation...
  4. pmc Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Immunother 33:155-66. 2010
    ..These findings indicate that stimulation with DC/tumor fusions provides a unique platform for subsequent expansion with anti-CD3/CD28 in adoptive T-cell therapy of cancer...
  5. doi request reprint MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells
    Dina Stroopinsky
    Beth Israel Deaconess Medical Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 73:5569-79. 2013
    ..Our results establish that MUC1 is highly expressed in AML stem cells and they define the MUC1-C subunit as a valid target for their therapeutic eradication...
  6. pmc Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
    Baldev Vasir
    Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Immunol 181:808-21. 2008
    ..In contrast, exposure to TLR agonists, stimulatory cytokines, and anti-CD3/CD28 enhances vaccine efficacy by limiting the regulatory T cell response and promoting expansion of activated effector cells...
  7. pmc Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Blood 117:393-402. 2011
    ..Vaccination with DC/multiple myeloma fusions was feasible and well tolerated and resulted in antitumor immune responses and disease stabilization in a majority of patients...
  8. pmc Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC)
    Baldev Vasir
    Dana Farber Cancer Institute, Center for Molecular Orthopaedics, Brigham and Women s Hospital, Boston, MA, USA
    J Immunother 35:555-69. 2012
    ..These data suggest that Tregs expanded by rF-PANVAC-DCs, exhibit immunosuppressive properties potentially mediated by Th2 cytokines, but simultaneous expression of Th1 and Th17-associated factors suggests a high degree of plasticity...
  9. ncbi request reprint Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation
    Baldev Vasir
    Department of Medical Oncology and Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 129:687-700. 2005
    ..These findings demonstrate that tumour cell fusion induces DC maturation and the development of an activated phenotype necessary for their effectiveness as cancer vaccines...
  10. doi request reprint Lenalidomide enhances anti-myeloma cellular immunity
    Katarina Luptakova
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Cancer Immunol Immunother 62:39-49. 2013
    ....
  11. pmc The Medical Research Council Myeloma IX trial: the impact on treatment paradigms
    Paul G Richardson
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Haematol 88:1-7. 2012
    ....
  12. pmc MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells
    Li Yin
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:4863-70. 2011
    ..These findings indicate that MUC1-C function is of importance to AML cell self-renewal and that inhibition of MUC1-C represents a potential therapeutic approach to induce terminal differentiation of AML cells...
  13. doi request reprint Dendritic/tumor fusion cells as cancer vaccines
    David Avigan
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Semin Oncol 39:287-95. 2012
    ..A current focus of research interest lies in enhancing response to cancer vaccines, by combining vaccination with tumor cytoreduction, regulatory T-cell depletion, and blockade of critical inhibitory pathways...
  14. ncbi request reprint Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Selective Control of JC Virus Reactivation
    CHEN SABRINA TAN
    Center of Virology and Vaccine Research, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts Division of NeuroVirology, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Electronic address
    Biol Blood Marrow Transplant 20:992-9. 2014
    ..This prospective study in HSCT patients provides a model of interactions between the host immune response and viral activation in multiple compartments during the recovery of the immune system. ..
  15. ncbi request reprint Dendritic cell fusion vaccines for cancer immunotherapy
    Jacalyn Rosenblatt
    Hematologic Malignancy Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA
    Expert Opin Biol Ther 5:703-15. 2005
    ..Preliminary results demonstrate that generation of a vaccine is feasible and that vaccination is associated with minimal toxicity. Immunological and clinical responses have been found in a subset of patients...
  16. ncbi request reprint Management of relapsed and relapsed/refractory multiple myeloma
    Jacob P Laubach
    Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 9:1209-16. 2011
    ..Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM...
  17. pmc MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells
    Takeshi Kawano
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 67:11576-84. 2007
    ..These findings indicate that MUC1 stabilizes Bcr-Abl and contributes to the pathogenesis of CML cells by promoting self renewal and inhibiting differentiation and apoptosis...
  18. pmc Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy
    CHEN SABRINA TAN
    Department of Medicine, Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Acquir Immune Defic Syndr 60:244-8. 2012
    ..0004). Blocking the PD-1 receptor increased JCV-specific T-cell immune response in a subgroup of PML patients...
  19. ncbi request reprint Can leukemia-derived dendritic cells generate antileukemia immunity?
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Hematologic Malignancy Bone Marrow Transplant Program, 330 Brookline Avenue, KS 121, Boston, MA 02215, USA
    Expert Rev Vaccines 5:467-72. 2006
    ..However, the efficacy of this approach may be limited by intrinsic abnormalities in the malignant clone that prevent differentiation towards a normal DC phenotype...
  20. doi request reprint Cellular immunotherapy for multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Best Pract Res Clin Haematol 21:559-77. 2008
    ....
  21. doi request reprint Immunotherapy for multiple myeloma
    Jacalyn Rosenblatt
    Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA
    Expert Rev Hematol 7:91-6. 2014
    ..Encouraging results have been demonstrated both pre-clinically and in clinical trials. In this review, we summarize the clinical data evaluating immunotherapeutic approaches for the treatment of multiple myeloma. ..
  22. pmc Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial
    Corey Cutler
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    Blood 122:1510-7. 2013
    ..039). Rituximab can prevent systemic corticosteroid-requiring chronic GVHD after peripheral blood stem cell transplantation and should be tested in a prospective randomized trial...
  23. doi request reprint Immunotherapy for renal cell carcinoma
    Jacalyn Rosenblatt
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Hematol Oncol Clin North Am 25:793-812. 2011
    ..This review describes how improvements in patient selection, combination therapy, and investigational agents might expand and better define the role of immunotherapy in metastatic RCC...